Pamired 30 Injection
Pamidronate
30gm
Dr. Reddy's Laboratories.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Pamired 30 Injection is used for:
Hypercalcemia of Malignancy, Paget's Disease, Osteolytic Bone Metastases of Breast Cancer, Osteolytic Bone Lesions of Multiple Myeloma
Adult Dose
Intravenous
Hypercalcemia of Malignancy
Moderate hypercalcemia (ie, corrected serum calcium 12-13.5 mg/dL): 60-90 mg single-dose IV infusion over 2-24 hours
Severe hypercalcemia (ie, corrected serum calcium > 13.5 mg/dL): 90 mg single-dose IV infusion over 2-24 hours
May repeat after at least 7 days in patients showing partial or complete response if serum calcium does not remain in normal range
Paget's Disease
30 mg IV infused over 4 hours qDay for 3 consecutive days (ie, total cumulative dose 90 mg)
Osteolytic Bone Metastases of Breast Cancer
90 mg IV infusion over 2 hours q3-4Weeks
Osteolytic Bone Lesions of Multiple Myeloma
90 mg IV infusion over 4 hours qMonth
Child Dose
Safety & efficacy not established
Renal Dose
Renal impairment: Max infusion rate: 20 mg/hr.
CrCl (ml/min) Dosage Recommendation
<30 Avoid, unless in life-threatening cases.
Administration
IV Preparation
Reconstitute by adding 10 mL of SWI to a vial
May be further diluted in 250-1000 mL of 1/2NS, NS or D5W
IV Administration
Slowly infuse over 2-24 hours
Longer infusion may reduce risk of nephrotoxicity
Contra Indications
Pregnancy, Hypersensitivity, Lactation.
Precautions
Patient w/ cardiac disease, previous thyroid surgery; pre-existing anaemia, leucopenia or thrombocytopenia. Renal impairment. Elderly. Pregnancy. Patient Counselling Rarely, this drug may cause somnolence and/or dizziness, if affected, do not drive or operate machinery. Maintain good oral hygiene and adequate hydration. Monitoring Parameters Monitor renal function; serum electrolytes, including Ca, phosphate, Mg and K; CBC w/ differential. Perform routine dental check up.
Pregnancy-Lactation
Interactions
Enhanced hypocalcaemic effect w/ aminoglycosides. Increased nephrotoxic effect w/ thalidomide. Enhanced adverse effects w/ NSAIDs. Synergistic effect w/ calcitonin in patients w/ severe hypercalcaemia. Concomitant use w/ other bisphosphonates, other antihypercalcaemic agents and calcitonin may lead to hypocalcaemia w/ associated clinical symptoms (e.g. paraesthesia, tetany, hypotension).
Adverse Effects
Side effects of Pamidronate :
Renal toxicity, fever and flu-like symptoms, CNS effects (e.g. agitation, confusion, dizziness, lethargy, insomnia, somnolence), seizures, hallucinations, hypocalcaemia, hypophosphataemia, hypomagnesaemia, hypokalaemia, hypotension, HTN, anaemia, thrombocytopenia, lymphocytopenia; osteonecrosis of the jaw (cancer patient), femoral fractures (long term treatment).
Rarely, hypernatraemia, hyperkalaemia, bronchospasm, interstitial pneumonitis.
Mechanism of Action
Pamidronic acid inhibits bone resorption and decreases mineralisation by suppressing the accession of osteoclast precursors onto the bone, thus preventing transformation into mature, absorbing osteoclasts.
Note
Pamired 30 30gm Injection manufactured by Dr. Reddy's Laboratories.. Its generic name is Pamidronate. Pamired 30 is availble in Nepal.
Farmaco Nepal drug index information on Pamired 30 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.